Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter December 2, 2014

Nutrition: a promising route for prevention and management of obesity-related nonalcoholic fatty liver disease

  • Giovanni Tarantino EMAIL logo

Abstract

When dealing with the treatment of obesity-linked illnesses – in particular nonalcoholic fatty liver disease – beyond diet, various nutritional ingredients are reported to be useful as silymarin, spirulina, choline, folic acid, methionine and vitamin E, all of them showing promising but not definite results. An emerging field of study is represented by prebiotics/probiotics and restoration of normal gut flora, which could play a fundamental role diet and various its components. It is noteworthy to point out that both improving or reducing the severity of nonalcoholic fatty liver disease bear a positive consequence on evolution of atherosclerosis and its cardiovascular-associated disease, such as coronary artery disease, even though the involved immunologic mechanisms are gaining greater credit in the most recent literature, without excluding the role of nutrition in modulating the acquired immunity in this condition.


Corresponding author: Giovanni Tarantino, Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Italy; and Centro Ricerche Oncologiche di Mercogliano, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Italy, E-mail:

References

1. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002;10:97S–104S.10.1038/oby.2002.202Search in Google Scholar PubMed

2. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293–303.10.1111/j.1440-1746.2007.04824.xSearch in Google Scholar PubMed

3. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumié A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clément K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005;54:2277–86.10.2337/diabetes.54.8.2277Search in Google Scholar PubMed

4. Deng W, Wang X, Xiao J, Chen K, Zhou H, Shen D, Li H, Tang Q. Loss of regulator of g protein signaling 5 exacerbates obesity, hepatic steatosis, inflammation and insulin resistance. PLoS One 2012;7:e30256.10.1371/journal.pone.0030256Search in Google Scholar PubMed PubMed Central

5. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013;19:802–12.10.3748/wjg.v19.i6.802Search in Google Scholar PubMed PubMed Central

6. Cuthbertson DJ, Irwin A, Sprung VS, Jones H, Pugh CJ, Daousi C, Adams VL, Bimson WE, Shojaee-Moradie F, Richardson P, Umpleby AM, Wilding JP, Kemp GJ. Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. Clin Sci (Lond) 2014;127:655–63.10.1042/CS20130404Search in Google Scholar PubMed

7. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319–27.10.1097/MD.0b013e3182779d49Search in Google Scholar PubMed

8. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2014;S1542–65.Search in Google Scholar

9. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015–25.10.1172/JCI28898Search in Google Scholar PubMed PubMed Central

10. Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:833–49.10.3945/ajcn.114.086314Search in Google Scholar PubMed PubMed Central

11. Shen H, Shahzad G, Jawairia M, Bostick RM, Mustacchia P. Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2014;40:1066–73.10.1111/apt.12944Search in Google Scholar PubMed

12. Finelli C, Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol 2012;18:6797–807.10.3748/wjg.v18.i46.6790Search in Google Scholar PubMed PubMed Central

13. Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G. Should visceral fat be reduced to increase longevity? Ageing Res Rev 2013;12:996–1004.10.1016/j.arr.2013.05.007Search in Google Scholar PubMed

14. Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:9338–44.Search in Google Scholar

15. Tarantino G. Gut microbiome, obesity-related comorbidities, and low-grade chronic inflammation. J Clin Endocrinol Metab 2014;99:2343–6.10.1210/jc.2014-2074Search in Google Scholar PubMed

16. Tarantino G, Costantini S, Finelli C, Capone F, Guerriero E, La Sala N, Gioia S, Castello G. Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with nonalcoholic Fatty liver disease. PLoS One 2014;9:105610.10.1371/journal.pone.0105610Search in Google Scholar PubMed PubMed Central

Received: 2014-10-27
Accepted: 2014-10-29
Published Online: 2014-12-2
Published in Print: 2014-11-1

©2014 by De Gruyter

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/hmbci-2014-0034/html
Scroll to top button